IPSEN (OTCMKTS:IPSEY – Get Free Report) shares gapped down before the market opened on Monday . The stock had previously closed at $48.52, but opened at $45.7620. IPSEN shares last traded at $45.7620, with a volume of 539 shares.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on IPSEY shares. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Finally, Zacks Research upgraded shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, IPSEN currently has a consensus rating of “Hold”.
Read Our Latest Stock Report on IPSEY
IPSEN Stock Down 4.1%
About IPSEN
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Recommended Stories
- Five stocks we like better than IPSEN
- One Short- and One Long-Term ETF for Quantum Computing Bulls
- The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
- Why Micron Is Doubling Down While the HBM Shortage Persists
- China’s Helium Ban Could Reshape the AI Supply Chain
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
